Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Oct 29;12(3):806–828. doi: 10.1080/21645515.2015.1102804

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Taylor & Francis

PMC Copyright notice

Figure 9. — Schematic illustration of strategies to enhance the therapeutic efficacy of DC-based vaccines via PLGA particles. (a) PLGA particles are linked to specific antibodies against DC receptors (e.g., DEC-205 and CD11c) to target vaccine components which are loaded in these particles specifically to DCs. Therefore, DC maturation and consequently CD8⁺ activation are occurred. (b) In another strategy, siRNA of suppressive gene can either co-encapsulate in PLGA particles containing antigen or encapsulate in distinct PLGA particle with TLR ligands and co-administer with antigen loaded-PLGA particles. Then, DCs are activated by these PLGA particles and antigen specific immunity is induced.